Novel pyrrole based triazole moiety as therapeutic hybrid: synthesis, characterization and anti-Alzheimer potential with molecular mechanism of protein ligand profile
Authors:
Open Access
- 9 November 2024
- journal article
- research article
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-18
Abstract
As a springboard to explore novel potent inhibitors of cholinesterase enzymes (AChE and BChE) responsible for causing Alzheimer disorder, the current study was conducted to synthesize pyrrole derived triazole based Schiff base scaffolds by facile synthetic route. These compounds were validated by 1HNMR, 13CNMR and HREI-MS. All these scaffolds (1–16) were examined for their inhibitory activity against AChE and BChE in contrast to Donepezil (10.20 ± 0.10 and 10.80 ± 0.20 µM) and Allanzanthone (12.40 ± 0.10 and 13.10 ± 0.10 µM). All pyrrole derived triazole based Schiff base scaffolds (1–16) showed varied range of inhibitory potentials against acetylcholinesterase and butyrylcholinesterase enzymes with lowest inhibition concentration values ranging from 5.10 ± 0.40–27.10 ± 0.10 µM (for AChE) and 5.60 ± 0.30–28.40 ± 0.30 µM (for BChE). SAR analysis of these derivatives revealed analog 7 as lead molecule against targeted enzyme, while analog 6 and 11 were ranked as second and third most potent scaffolds. Binding affinity and selectivity of potent molecules against targeted enzymes were examined by molecular docking and obtained results showed that potent molecule have versatile significant binding interactions with stated enzymes. Furthermore, safety profiles of potent analogues were predicted via ADMET protocols.Keywords
Funding Information
- King Saud University ((RSPD2024R812))
This publication has 45 references indexed in Scilit:
- Efficient, rapid, and high‐yield synthesis of aryl Schiff base derivatives and their in vitro and in silico inhibition studies of hCA I, hCA II, AChE, and BuChEArchiv der Pharmazie, 2024
- Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes MellitusChemistry & Biodiversity, 2023
- Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effectsJournal of Biochemical and Molecular Toxicology, 2023
- Synthesis and Evaluation of Quinazolin‐4(3 H )‐one Derivatives as Multitarget Metabolic Enzyme Inhibitors: A Biochemistry‐Oriented Drug DesignChemistrySelect, 2023
- Synthesis, Characterization, Bioactivity Impacts of New Anthranilic Acid Hydrazones Containing Aryl Sulfonate Moiety as Fenamate IsosteresChemistrySelect, 2023
- New Diacetic Acids Containing Quinazolin‐4(3 H )‐one: Synthesis, Characterization, Anticholinergic Properties, DFT Analysis and Molecular Docking StudiesChemistrySelect, 2023
- Carboxylate‐ and Sulfonate‐Containing Quinazolin‐4(3H)‐one Rings: Synthesis, Characterization, and Carbonic Anhydrase I–II and Acetylcholinesterase Inhibition PropertiesChemistrySelect, 2023
- Design, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivativesArchiv der Pharmazie, 2021
- Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s diseaseActa Neuropathologica, 2014
- Evaluation of the thiazole Schiff bases as $\upbeta $ β -glucuronidase inhibitors and their in silico studiesMolecular Diversity, 2014